Yettwaleqqem
WHO updated recommendations on HIV clinical management: recommendations for a public health approach
World Health Organization
Tuḍḍiwin n tɣawsiwin 2025TAFFA N TMUSNIWIN TUSNANIN
Ilugan n usḍibbi
Af-d ilugan unṣiben, arraten n umtawa d yileqman i d-ssufɣen yimusnawen d tedbirtin n ṣṣeḥḥa.
Iɣbula unṣiben, yettwamanenTuddsiwin tusnawin d tedbirtin n ṣṣeḥḥa
Isallen yettwaleqqmenAsenqed ussnan ameɣlal
Anekcum s war azal i yimseɣtayenI ɣur n temɣiwent n yimdanen n tẓṛi
ASNAS ASEM
Iwellihen klinikiyen, anda tebɣuḍ
Snirem iwellihen imuddisen unṣiben d yilugan klinikiyen deg usnas ASEM.
Sader asnas ASEMTisuffaɣ d ileqman ixataren
Wali isuffeɣen ineggura
Yettwaleqqem
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
European Society of Cardiology
Tasleḍt n wul 2025
Asuffeɣ unṣib
Retinopathy of prematurity: Strategies to optimize screening and management
Canadian Paediatric Society
Taseḍṛit n warrac 2026Akk yilugan (525 igmuḍ)
Imsizzel
Archived 46: Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 46: Summary of NACI statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech C...
Archived 46: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age [2022-10-21]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 46: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6...
Archived 47: Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 47: Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Rec...
Archived 48: Summary of NACI statement of December 9, 2022: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 48: Summary of NACI statement of December 9, 2022: Updated recommendations on the use of COVID-19...
Archived 48: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration [December 9, 2022]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archived 48: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years...
Archive 30: Summary of updates in the Canadian Immunization Guide of June 3, 2022: Updated guidance on COVID-19 vaccines in Canada [2022-06-03]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archive 30: Summary of updates in the Canadian Immunization Guide of June 3, 2022: Updated guidance on COVI...
Archive 38: Summary of updates in the Canadian Immunization Guide of June 21 2022: Updated guidance on COVID-19 vaccines in Canada [2022-06-21]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archive 38: Summary of updates in the Canadian Immunization Guide of June 21 2022: Updated guidance on COVI...
Archive 40: Summary of updates in the Canadian Immunization Guide of August 29, 2022: Updated guidance on COVID-19 vaccines in Canada [2022-08-29]
National Advisory Committee on Immunization
Official National Advisory Committee on Immunization document (2022) on “Archive 40: Summary of updates in the Canadian Immunization Guide of August 29, 2022: Updated guidance on C...
2022 Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
American Association of Clinical Endocrinology
Official American Association of Clinical Endocrinology document (2022) on “2022 Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in...
2022 Consensus Statement on Minimally Invasive Procedures for Benign and Malignant Thyroid Lesions
American Association of Clinical Endocrinology
Official American Association of Clinical Endocrinology document (2022) on “2022 Consensus Statement on Minimally Invasive Procedures for Benign and Malignant Thyroid Lesions”. Thi...